Switzerland-based Ferring Pharmaceuticals is launching its NOCDURNA (desmopressin acetate) in the United States, it was reported yesterday.

The product is a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void. It is claimed to offer a fast-acting, effective treatment that targets the kidneys, the underlying cause of NP.

The sublingual tablet formulation and sex-specific dosing has been indicated to decrease night-time urination by nearly half in adults 18 years and older.

The product received approval from the US Food and Drug Administration (FDA) based on three double-blind placebo-controlled, multi-centre, randomised trials and one open-label extension trial of up to three years in patients 18 years and older.